gowebcasting uses cookies in order to improve your online experience. By continuing to use gowebcasting.com, you accept our privacy policy.


Thursday, May 24, 2012 at 11:30amET / 12:30pmAT

Immunovaccine (TSX-V: IMV) is a clinical stage biotechnology company developing infectious disease and therapeutic cancer vaccines for human health.  The company continues to strengthen its vaccine pipeline through licensing and strategic partnering. With positive clinical safety data and recent partnerships with LIAI, NIH, Defence Research & Development Canada, and NCI the value of their Depovax™ vaccine delivery system has been significantly enhanced.

For more information pleae visit the company website at: www.imvaccine.com

The following information is required to view this webcast.
Please complete all of the information to continue.

Email *
First Name *
Last Name *
Company *

The Bottom Line

CO2 emissions saved by using gowebcasting viewing this webcast:

Share this page on: